Wednesday, April 21, 2021 9:54:06 PM
Scooter, all interesting CYDY questions and observations.
On why there was no impact on the new rule changes for short sellers and margin maintenance requirements. This is concerning a deep fear held by broker firms about shorted securities price spikes similar to GameStop. Such upward spikes can force Broker Firms out of business in one day.
Why no impact? Very few realize the margin maintenance on a stock shorted at 2.3$ is 2.5$. Yes, more than the sell price.
But, But what is it if the stock is 2$.
Answer. Still 2.5$ If 5$ it was 2.5$.
Exactly where that requirement rests today is obviously something I have not experienced.
Hence, those short CYDY positions are already at 100%. Cant go over 100%, as far as I know. Meaning no short was forced to add funds. Therefore no short was extra nervous because I would estimate that 99% of large shorts have known this for months.
On longs not buying. The exact % of long buys and short seller buys is very difficult to estimate. In the 1980s 99.9% of buys were longs. Shorts were a small problem in those years. Today; I can not nail the %%. It traded an average amount. Some longs sold others bought. Not an important day to remember.
The class action suits? I consider the suits a joke. If called as an expert witness I would say exactly that. In exactly those well spoken words.
Reverse split. Very improbable. 1 in a 1000. I can see 5 or more catalysts in the works that can move us hugely, Hugely higher. A reverse is a waste of time and would only help short sellers for a short time period.
Bankruptcy? 1 in a million. WHY?
Because we, CYDY is in very interesting medical indications. Management has been schooled by the FDA and now know what to do in the near future. The next trial has a slim to very slim chance to be ignored by the FDA.
To raise capital all management needs to do is do an underwriting and stop doing stupidly small 25,000,000$ raises. Do real money. 100 to 200 million. Wham. It can be fid in a month start to finish.
Again, I liked to questions or observations.
On why there was no impact on the new rule changes for short sellers and margin maintenance requirements. This is concerning a deep fear held by broker firms about shorted securities price spikes similar to GameStop. Such upward spikes can force Broker Firms out of business in one day.
Why no impact? Very few realize the margin maintenance on a stock shorted at 2.3$ is 2.5$. Yes, more than the sell price.
But, But what is it if the stock is 2$.
Answer. Still 2.5$ If 5$ it was 2.5$.
Exactly where that requirement rests today is obviously something I have not experienced.
Hence, those short CYDY positions are already at 100%. Cant go over 100%, as far as I know. Meaning no short was forced to add funds. Therefore no short was extra nervous because I would estimate that 99% of large shorts have known this for months.
On longs not buying. The exact % of long buys and short seller buys is very difficult to estimate. In the 1980s 99.9% of buys were longs. Shorts were a small problem in those years. Today; I can not nail the %%. It traded an average amount. Some longs sold others bought. Not an important day to remember.
The class action suits? I consider the suits a joke. If called as an expert witness I would say exactly that. In exactly those well spoken words.
Reverse split. Very improbable. 1 in a 1000. I can see 5 or more catalysts in the works that can move us hugely, Hugely higher. A reverse is a waste of time and would only help short sellers for a short time period.
Bankruptcy? 1 in a million. WHY?
Because we, CYDY is in very interesting medical indications. Management has been schooled by the FDA and now know what to do in the near future. The next trial has a slim to very slim chance to be ignored by the FDA.
To raise capital all management needs to do is do an underwriting and stop doing stupidly small 25,000,000$ raises. Do real money. 100 to 200 million. Wham. It can be fid in a month start to finish.
Again, I liked to questions or observations.
Recent CYDY News
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
